Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Acta Inform Med. 2008; 16(3): 124-126


The Gen5 Software and Automated Microreader ELx800 in analysis of Anti-CCP Antibodies

Sekib Sokolovic, Jasenko Karamehic, Dzemal Subasic, Zahida Drace, Lamija Zecevic, Marina Delic-Sarac.




Abstract

Aim: Detection of Anti-CCP antibodies in rheumatoid arthritis patients using Automated Microreader and Gen5 Software for analysis and data processing. Material and method: Total of 776 blood samples from inflammatory arthritis patients were obtained. Statistical analysis for positive and negative results was calculated and test values were compared. Results: Anti-CCP test was found positive (>25U/ml) in 32,8% of blood samples. The all positive test results were in rheumatoid arthritis patients with 95% specificity. Negative test results was found in 67,2% of blood samples that were drawn from all IgM RF negative individuals, reactive arthritis and osteoarthritis patients as well as in some end-stage rheumatoid arthritis disease. Mean value of positive results was very high: 599,62 U/ml. Conclusion: The anti-CCP test is highly specific test in Rheumatoid arthritis. The positive test in early undifferentiated inflammatory polyarthritis provides new laboratory diagnostic inflammatory marker and helps practitioners to confirm diagnosis of early rheumatoid arthritis. Microplate reader and Genf4 Software using ELISA method is essential automotive tool for extensive on-board data obtained analysis.

Key words: Gen5 software, Anti-CCP antibodies.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.